Quest Diagnostics Launches First-To-Market Consumer-Initiated Blood Test For Alzheimer’s Disease Risk Assessment

Quest Diagnostics launched AD-Detect™ Test for Alzheimer's Disease, a blood test available for consumer purchase that helps assess potential risk of developing Alzheimer's disease based on a brain protein (beta amyloid) that contributes to the condition. Physician oversight is included in the offering, to help individuals interpret results and determine next steps for continued care, including recommendations for follow-up with their physician or a specialist. The test is intended for adults ages 18 and older in the United States (except in Alaska, Arizona, and Hawaii).

Detection of Alzheimer's disease has traditionally involved screening individuals for . . .